| Document |
Document Title |
|
WO/2024/000067A1 |
There is provided a method of treating an immune cytopenia in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound of formula (I) wherein R1, R2, R3 and R4 are as defined herein.
|
|
WO/2024/002223A1 |
The present invention relates to a heterocyclic derivative as an inhibitor, a method for preparing same, and use thereof. In particular, the present invention relates to a compound represented by general formula (I), a method for prepari...
|
|
WO/2023/250059A1 |
Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourett...
|
|
WO/2023/244710A1 |
The invention provides novel anilino-pyrazole derivatives as a cyclin-dependent kinase 2 (CDK2) inhibitors. The invention also provides pharmaceutical compositions comprising the compounds and methods thereof for treating various conditi...
|
|
WO/2023/243678A1 |
The present invention provides a pyrazole compound represented by formula (1) or a salt thereof, and a novel bactericide containing same as an active ingredient, particularly, a bactericide for agricultural and horticultural use. In the ...
|
|
WO/2023/242576A1 |
The present invention relates to crystalline forms of the synthetic, non-natural cannabinoid (1'R,2'R)-5'-methyl-4-(1-methyl-1H-pyrazol-4-yl)-2'-(prop-1-
en-2-yl)-1',2',3',4'-tetrahydro-[1,1'- biphenyl]-2,6-diol, methods for their produc...
|
|
WO/2023/239839A1 |
Disclosed herein are compounds having an isoxazole core or an oxadiazole core or a pharmaceutically acceptable salt thereof and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excess...
|
|
WO/2023/239846A1 |
The present application provides heterocyclic compounds of formula (I) that modulate the activity of the PI3Ka, which are useful in the treatment of various diseases, including cancer.
|
|
WO/2023/234425A1 |
The present invention provides a novel active ester of an amino acid to be used for amino acylation of tRNA, said ester being capable of reducing risks to safety and waste. The present invention provides a compound represented by formula...
|
|
WO/2023/226344A1 |
An ionic liquid composition and a preparation method therefor. The ionic liquid composition comprises the following components in percentages by weight: 80-90% of ionic liquid A, and 10-20% of ionic liquid B. By compounding the ionic liq...
|
|
WO/2023/229293A1 |
The present invention relates a bicycle derivative and a pharmaceutical composition comprising same as an active ingredient for the prevention or treatment of cancer. Found to have ACC inhibitory activity involved in the inhibitory mecha...
|
|
WO/2023/230540A2 |
The invention relates to compounds that are useful for the prevention or treatment of TRPM3 mediated disorders, more in particular disorders selected from pain and inflammatory hypersensitivity. The invention also relates to a method for...
|
|
WO/2023/225327A1 |
Compounds, compositions, and methods for making and using the compounds for treatment of cancer are provided herein. Mechanistically, these compounds were found to bind to RPS23 and were effective in activating the inducible stress respo...
|
|
WO/2023/223055A1 |
This invention relates to compounds that can be used to treat viral infections. The compounds of the present invention are papain-like protease (PLpro) inhibitors.
|
|
WO/2023/224981A1 |
Described herein are HSD17B13 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of liver disease, metabolic disease, or cardiovascular disease, such...
|
|
WO/2023/225244A1 |
The present disclosure provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is ...
|
|
WO/2023/223253A1 |
The present invention provides a process for the preparation of ruxolitinib or a pharmaceutically acceptable salt thereof. In particular, the present invention provides a process for the preparation of crystalline (R)-ruxolitinib phospha...
|
|
WO/2023/215279A1 |
The invention relates to the unexpected discovery that the oral administration of charged sodium channel blockers, also called "Nocions," alleviates inflammation in intestinal inflammatory diseases, such as inflammatory bowel disease (IB...
|
|
WO/2023/211853A1 |
Disclosed herein are compounds comprising a pyrazole core and pharmaceutically acceptable salts thereof, and compositions useful for preventing and/or treating a neurological disorder, a disorder associated with excessive neuronal excita...
|
|
WO/2023/209678A1 |
The present invention is a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The present invention also relates to the derivatives of the said compound of Formula (I). The present invention relates to method of prep...
|
|
WO/2023/212063A1 |
A method, composition and kit for the treatment of fibrotic lung disease are disclosed. The method utilizes a combination product for inhalation comprising a therapeutic amount of a dry powder formulation provided in an inhaler to be adm...
|
|
WO/2023/210599A1 |
The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
|
|
WO/2023/209722A1 |
The invention relates generally to the field of compositions comprising one or more trehalose conjugates and is directed to methods of using the same such as for treating a disease or a disorder in a subject.
|
|
WO/2023/209651A1 |
The present invention relates to bicyclic heterocycle compounds, to their preparation and to their therapeutic use. Specifically, the present invention relates to the compounds represented by formula (I), a pharmaceutically acceptable sa...
|
|
WO/2023/208143A1 |
The present application relates to a pyrazole-substituted cyclopentanol ester derivative and use thereof, and in particular to a compound represented by formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
|
|
WO/2023/204967A1 |
NLRP3 selective inhibitors (NSIs) as anti-inflammatory agents are provided, as are methods of using NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as Alzheimer's disease, Park...
|
|
WO/2023/203066A1 |
The present invention relates to a novel mixture of nitrification inhibitors comprising (i) an alkoxypyrazole compound of formula (I) or a salt, tautomer, or N-oxide thereof, and (ii) a nitrification inhibitor system comprising (A) at le...
|
|
WO/2023/202545A1 |
Provided in the present invention is the use of a diphenyl pyrazole compound represented by general formula (I) or a pesticidally acceptable salt thereof as a herbicide synergist. The compound is an inhibitor targeting GSTs in farmland w...
|
|
WO/2023/200441A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formula (I) which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumo virus (HMPV) inhibitors. ...
|
|
WO/2023/196518A1 |
Formula (I) or a salt (e.g., pharmaceutically acceptable salt) or stereoisomer thereof, wherein X, Y, R1a, R1b, R2, R3, R4s, R5, p, and n are as defined herein. Use of the compounds as a component of a pharmaceutical compositions and met...
|
|
WO/2023/196556A1 |
Disclosed herein are compounds suitable for use in the treatment of disorders, e.g., diabetic disorder, a dyslipidemia disorder, a cardiovascular disorder, an inflammatory disorder, a hepatic disorder, cancer, or obesity or co-morbiditie...
|
|
WO/2023/196517A1 |
(I) or a stereoisomer or salt (e.g., pharmaceutically acceptable salt) thereof, wherein R1, R2, R3, R4, R5, p, m, and n are as defined herein. Use of the compounds as a component of a pharmaceutical compositions and methods for their use...
|
|
WO/2023/194496A1 |
A process for the preparation of compound of formula (I) is provided: where R, R1, R2, R3 and R4 are as defined in the description.
|
|
WO/2023/192534A1 |
Described herein are CDK9 degraders that include a CDK9 binding moiety, such as AT7519 or VIP152, conjugated to a E3 ubiquitin ligase binding moiety, such as thalidomide, lenalidomide, or pomalidomide. These degraders can induce the ubiq...
|
|
WO/2023/191201A1 |
The present invention provides a novel pyrazole derivative compound represented by chemical formula I, a stereoisomer thereof, a solvate thereof, an isotopic variant thereof, a tautomer thereof, or a pharmaceutically acceptable salt ther...
|
|
WO/2023/192817A1 |
Provided herein are compounds of Formula (I). Methods for the preparation of the compounds of Formula (I) and intermediates useful in the preparation of the compounds of Formula (I) are described herein. The compounds of Formula (I) may ...
|
|
WO/2023/186773A1 |
The present invention relates to substituted 3-amino indazole derivatives as kinase inhibitors and in particular as inhibitors of CDK11 families. Due to the key role of protein kinases, in particular of CDK11, in the regulation of cellul...
|
|
WO/2023/185821A1 |
Disclosed is a 1,4-diheterocyclic substituted aromatic ring or aromatic heterocyclic compound represented by formula (I). The compound can effectively inhibit the generation of 20-HETE, and has high activity, high selectivity and good ph...
|
|
WO/2023/192506A1 |
Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.
|
|
WO/2023/186058A1 |
Disclosed are an indazole compound represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising said compound, and use of said compound as a TEAD inhibitor, particularly use thereof in the pr...
|
|
WO/2023/183463A1 |
Provided herein is a method of potentiating a cytotoxic effect of temozolomide against glioblastoma cells in a subject in need thereof, the method including administering to the subject a combination of: a therapeutically effective amoun...
|
|
WO/2023/177249A1 |
The present invention pertains to a novel binary Histone deacetylase (HDAC) inhibitor, and a pharmaceutical composition containing same. More specifically, the compound according to the present invention exhibits more selective and super...
|
|
WO/2023/177250A1 |
The present invention relates to a novel heterocyclic inhibitor for histone deacetylase (HDAC), a novel therapeutic agent for HDAC-associated diseases, and a pharmaceutical composition comprising same. More specifically, a compound accor...
|
|
WO/2023/174397A1 |
Described herein are PKMYT1 (Myt1) inhibitors and pharmaceutical compositions comprising said inhibitors. The compounds and compositions are useful for the treatment of a disease or disorder associated with PKMYT1.
|
|
WO/2023/171305A1 |
An unsaturated hydrocarbon scavenger according to one aspect of the present disclosure has at least one carbon-carbon double bond, and contains a metal-organic framework that has a metal and a ligand coordinated to the metal, wherein the...
|
|
WO/2023/172846A1 |
Provided are compounds of Formula (I):and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with PPARG.
|
|
WO/2023/166450A1 |
The present invention relates to a compound represented by chemical formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof, and a pharmaceutical composition comprising same.
|
|
WO/2023/165168A1 |
The present invention relates to an application of a pyrazole derivative as a β 2 adrenergic receptor allosteric modulator, antagonist and agonist. An acetophenone or an acetophenone containing different substituents is used as an initi...
|
|
WO/2023/166303A1 |
The invention relates to compounds of formula (I): (I) and related aspects.
|
|
WO/2023/165334A1 |
The present invention provides keto amide derivatives and the pharmaceutical use thereof, belonging to the technical field of organic synthesis drugs. Specifically provided are a compound represented by formula I, or a pharmaceutically a...
|
